Lantern Pharma Inc.
NASDAQ:LTRN
Lantern Pharma Inc.
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
Clinical Milestones: Lantern Pharma achieved its most significant milestone to date with LP-184's Phase Ia trial meeting all primary endpoints and showing a 48% clinical benefit rate in evaluable cancer patients.
AI Platform Progress: The company advanced its RADR AI platform, showcasing deployable modules with high prediction accuracy and initiating commercialization to biopharma partners.
Cash Runway: Lantern ended Q3 with $12.4 million in cash, cash equivalents and marketable securities, providing expected runway into Q3 2026.
Cost Management: R&D expenses decreased year-over-year due to lower research and payroll costs, while general and administrative costs rose mainly from increased business development and patent expenses.
Strategic Expansion: The company detailed targeted precision oncology trials across high-value cancer indications and expanded its AI infrastructure, including launching the withZeta AI platform for rare cancers.
Upcoming Catalysts: Near-term milestones include a November KOL webinar on LP-184, a December data update on LP-300, and the commercial rollout of new AI modules.
